FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549	
-------------	------	-------	--

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Holmen Bob						2. Issuer Name and Ticker or Trading Symbol Sensei Biotherapeutics, Inc. [SNSE]								Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner							
	- 3. Da	Date of Earliest Transaction (Month/Day/Year)										r (give title		10% Ow Other (s							
(Last)	(F	irst)	(Middle)		07/1	07/10/2023									below)			below)			
C/O SENSEI BIOTHERAPEUTICS, INC.						4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable						
451 D STREET, SUITE 710														1 ′	Line) X Form filed by One Reporting Person						
(Street)					-									"		,	•	One Repor			
BOSTO	N M	A	02210												Persor	1					
	- Ru	Rule 10b5-1(c) Transaction Indication																			
(City) (State) (Zip)						Chock this how to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to															
				Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.																	
		Tab	le I - No	n-Deriv	vative	Sec	curities	Ac	quired, [Disp	osed c	of, or Be	enef	icially	y Owned	t					
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)					action		2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Dispos			rities Acquired (A) or			5. Amount of				7. Nature of Indirect Beneficial Ownership		
					Day/Year) if :					Disposed Of (D) (Instr. 3, 5)			Benefi Owned		ally Following	(D) or	or Indirect (Instr. 4)			
						v	Amount	(A) (D)	or F	Price	Reporte Transac (Instr. 3	ction(s)			(Instr. 4)						
Common Stock 07/10/					/2023				A		4,466	6 ⁽¹⁾ A S		\$0.00	25	25,598		D			
		T	able II -	Deriva	tive S	ecu	rities /	Acq	uired, Di	spc	sed of	, or Ber	nefic	ially	Owned			<u>'</u>			
				(e.g., p	outs, c	alls	, warra	ants	, options	s, c	onverti	ble sec	uriti	ies)							
1. Title of Derivative Security (Instr. 3)	ve Conversion Date Execution Date, or Exercise (Month/Day/Year) if any		4. Transaction Code (Instr. 8)		n of		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		urity	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)				
					Code	v	(A)	(D)	Date Exercisable		xpiration ate	Title	or Nur of	mber ares							
Stock							, ,	(-,		+			+	-			\dashv				
Option (Right to	\$1.22	07/10/2023			A		14,550		(2)	07	7/09/2033	Common Stock	14,	,550	\$0.00	14,550		D			

Explanation of Responses:

- 1. These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in full on the first anniversary of the date of grant, or July 10, 2024, subject to the Reporting Person's continuous service with the Issuer through such vesting date.
- 2. The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or July 10, 2024, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date.

Remarks:

/s/ Mark Ballantyne, Attorneyin-Fact ** Signature of Reporting Person

07/12/2023

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.